Analyst firms · Needham · TMDX
Needham TMDX price target and rating history
TransMedics Group Inc. (TMDX) · Health Care
Needham rates TransMedics Group Inc. (TMDX) Buy with a $148 price target, as of its latest action on Oct 23, 2025. It has published 4 rating actions on TMDX since August 2024, including 1 upgrade and 1 downgrade.
- Current rating
- Buy
- Price target
- $148
- Median target, all firms
- Too few
- Actions on TMDX
- 4
Needham price target on TMDX
Every Needham rating on TMDX
- Oct 23, 2025
- Nov 22, 2024DowngradeNeedham downgrades to Hold from Buy
- Oct 29, 2024
- Aug 21, 2024
How other firms rate TMDX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $120 | Oct 7, 2026 |
| UBS | Neutral | $80 | Jul 28, 2026 |
| Oppenheimer | Perform | May 6, 2026 |
Questions about Needham and TMDX
- What is Needham's price target for TMDX?
- Needham's latest stated price target for TransMedics Group Inc. (TMDX) is $148, from its action on Oct 23, 2025.
- What is Needham's rating on TMDX?
- Needham rates TMDX Buy, a bullish rating, as of Oct 23, 2025.
- When did Needham last change its view on TMDX?
- On Oct 23, 2025, Needham upgrades to Buy from Hold, price target $148.
All Needham ratingsTMDX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.